Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00782639 · ClinicalTrials.gov registry record · Phase 4
Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients
A Phase 4 study, sponsored by Bracco Diagnostics.
- Terminated
- Registry status
- Phase 4
- Development phase
- 23
- Enrollment target
NCT00782639 is a Phase 4 study that was terminated before completion, run by Bracco Diagnostics. The registered enrollment target is 23 participants.
The verdict
NCT00782639, a Phase 4 study, was terminated before completion, sponsored by Bracco Diagnostics.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the incidence of contrast-induced nephropathy (CIN) following the administration of iopamidol-370 (Iopamiro-370) and iodixanol-320 (Visipaque 320) in patients with moderate-to-severe chronic kidney disease and diabetes mellitus undergoing cardiac angiography.
Interventions
- DRUG iodixanol
- DRUG Iopamidol injection 76%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2009-03 |
| Est. Completion | 2009-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00782639
The ClinicalTrials.gov registry entry for NCT00782639 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which iodixanol is the first listed.
NCT00782639 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00782639 about?
NCT00782639 is a clinical study titled "Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients". The purpose of this study is to compare the incidence of contrast-induced nephropathy (CIN) following the administration of iopamidol-370 (Iopamiro-370) and iodixanol-320 (Visipaque 320) in patients with moderate-to-severe chronic kidney disease and diabetes mellitus undergoing cardiac angiography.
What is the current status of trial NCT00782639?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2009-03. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00782639?
The interventions under investigation include: iodixanol (DRUG), Iopamidol injection 76% (DRUG).
Who is sponsoring clinical trial NCT00782639?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.